Following the approval by the European Medicines Agency (EMA) of the monoclonal antibody Nirsevimab for the prevention of Respiratory Syncytial Virus (VRS) in the newborn, the Board of the Calendar for Life - of which the Italian Hygiene Society is a member - and the Italian Society of Neonatology (SIN) are calling for its inclusion in the National Immunization Calendar.
The Italian Society of Hygiene (SItI), the Italian Society of Pediatrics (SIP), the Italian Federation of Pediatricians (FIMP), and the Italian Federation of General Practitioners (FIMMG), which are on the Board of the Calendar for Life, along with the Italian Society of Neonatology (SIN) are the scientific societies that have expressed their position on the possible use of this monoclonal antibody.
